124 related articles for article (PubMed ID: 38491961)
1. Effects of pharmacogenetics on pharmacokinetics and toxicity of doxorubicin in Egyptian breast cancer patients.
Ebaid NF; Abdelkawy KS; Shehata MA; Salem HF; Magdy G; Hussein RRS; Elbarbry F
Xenobiotica; 2024 Mar; 54(3):160-170. PubMed ID: 38491961
[TBL] [Abstract][Full Text] [Related]
2. Association between the genetic polymorphisms of the pharmacokinetics of anthracycline drug and myelosuppression in a patient with breast cancer with anthracycline-based chemotherapy.
Cui L; Huang J; Zhan Y; Qiu N; Jin H; Li J; Huang H; Li H
Life Sci; 2021 Jul; 276():119392. PubMed ID: 33774021
[TBL] [Abstract][Full Text] [Related]
3. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.
Bray J; Sludden J; Griffin MJ; Cole M; Verrill M; Jamieson D; Boddy AV
Br J Cancer; 2010 Mar; 102(6):1003-9. PubMed ID: 20179710
[TBL] [Abstract][Full Text] [Related]
4. CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients.
Lal S; Sandanaraj E; Wong ZW; Ang PC; Wong NS; Lee EJ; Chowbay B
Cancer Sci; 2008 Oct; 99(10):2045-54. PubMed ID: 19016765
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Carbonyl Reductase 1 Safely Improves the Efficacy of Doxorubicin in Breast Cancer Treatment.
Jo A; Choi TG; Jo YH; Jyothi KR; Nguyen MN; Kim JH; Lim S; Shahid M; Akter S; Lee S; Lee KH; Kim W; Cho H; Lee J; Shokat KM; Yoon KS; Kang I; Ha J; Kim SS
Antioxid Redox Signal; 2017 Jan; 26(2):70-83. PubMed ID: 27357096
[TBL] [Abstract][Full Text] [Related]
6. Association of ABCB1 and SLC22A16 Gene Polymorphisms with Incidence of Doxorubicin-Induced Febrile Neutropenia: A Survey of Iranian Breast Cancer Patients.
Faraji A; Dehghan Manshadi HR; Mobaraki M; Zare M; Houshmand M
PLoS One; 2016; 11(12):e0168519. PubMed ID: 28036387
[TBL] [Abstract][Full Text] [Related]
7. Differential changes in the pharmacokinetics of doxorubicin in diethylnitrosamine-induced hepatocarcinoma model rats.
Pan J; Lu Y; Zhang S; Li Y; Sun J; Liu HC; Gong Z; Huang J; Cao C; Wang Y; Li Y; Liu T
Xenobiotica; 2020 Oct; 50(10):1251-1257. PubMed ID: 32375563
[TBL] [Abstract][Full Text] [Related]
8. Genetic Polymorphisms Affecting Cardiac Biomarker Concentrations in Children with Cancer: an Analysis from the "European Paediatric Oncology Off-patents Medicines Consortium" (EPOC) Trial.
Hellmann F; Völler S; Krischke M; Jamieson D; André N; Bisogno G; Boddy A; Hempel G
Eur J Drug Metab Pharmacokinet; 2020 Jun; 45(3):413-422. PubMed ID: 31981210
[TBL] [Abstract][Full Text] [Related]
9. Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients.
Lal S; Wong ZW; Jada SR; Xiang X; Chen Shu X; Ang PC; Figg WD; Lee EJ; Chowbay B
Pharmacogenomics; 2007 Jun; 8(6):567-75. PubMed ID: 17559346
[TBL] [Abstract][Full Text] [Related]
10. Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients.
Voon PJ; Yap HL; Ma CY; Lu F; Wong AL; Sapari NS; Soong R; Soh TI; Goh BC; Lee HS; Lee SC
Br J Clin Pharmacol; 2013 Jun; 75(6):1497-505. PubMed ID: 23116553
[TBL] [Abstract][Full Text] [Related]
11. Circulating miRNA Profiles of Doxorubicin-induced Cardiotoxicity in Breast Cancer Patients.
Todorova VK; Makhoul I; Wei J; Klimberg VS
Ann Clin Lab Sci; 2017 Mar; 47(2):115-119. PubMed ID: 28442511
[TBL] [Abstract][Full Text] [Related]
12. Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients.
Yu LR; Cao Z; Makhoul I; Daniels JR; Klimberg S; Wei JY; Bai JP; Li J; Lathrop JT; Beger RD; Todorova VK
Exp Biol Med (Maywood); 2018 Feb; 243(3):248-255. PubMed ID: 29224368
[TBL] [Abstract][Full Text] [Related]
13. GPR91 Receptor Mediates Protection against Doxorubicin-Induced Cardiotoxicity without Altering Its Anticancer Efficacy. An In Vitro Study on H9C2 Cardiomyoblasts and Breast Cancer-Derived MCF-7 Cells.
Dallons M; Alpan E; Schepkens C; Tagliatti V; Colet JM
Cells; 2020 Sep; 9(10):. PubMed ID: 32992522
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of target genes across doxorubicin disposition pathway: a review.
Lal S; Mahajan A; Chen WN; Chowbay B
Curr Drug Metab; 2010 Jan; 11(1):115-28. PubMed ID: 20302569
[TBL] [Abstract][Full Text] [Related]
15. Polymorphic Variations Associated With Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients.
Todorova VK; Makhoul I; Dhakal I; Wei J; Stone A; Carter W; Owen A; Klimberg VS
Oncol Res; 2017 Sep; 25(8):1223-1229. PubMed ID: 28256194
[TBL] [Abstract][Full Text] [Related]
16. Cinnamamide derivatives with 4-hydroxypiperidine moiety enhance effect of doxorubicin to cancer cells and protect cardiomyocytes against drug-induced toxicity through CBR1 inhibition mechanism.
Koczurkiewicz-Adamczyk P; Gąsiorkiewicz B; Piska K; Gunia-Krzyżak A; Jamrozik M; Bucki A; Słoczyńska K; Bojdo P; Wójcik-Pszczoła K; Władyka B; Kołaczkowski M; Pękala E
Life Sci; 2022 Sep; 305():120777. PubMed ID: 35792180
[TBL] [Abstract][Full Text] [Related]
17. Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy.
Kim KP; Ahn JH; Kim SB; Jung KH; Yoon DH; Lee JS; Ahn SH
Cancer Chemother Pharmacol; 2012 May; 69(5):1221-7. PubMed ID: 22271208
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers for Presymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients.
Todorova VK; Makhoul I; Siegel ER; Wei J; Stone A; Carter W; Beggs ML; Owen A; Klimberg VS
PLoS One; 2016; 11(8):e0160224. PubMed ID: 27490685
[TBL] [Abstract][Full Text] [Related]
19. microRNA miR-133a as a Biomarker for Doxorubicin-Induced Cardiotoxicity in Women with Breast Cancer: A Signaling Pathway Investigation.
Alves MT; da Conceição IMCA; de Oliveira AN; Oliveira HHM; Soares CE; de Paula Sabino A; Silva LM; Simões R; Luizon MR; Gomes KB
Cardiovasc Toxicol; 2022 Jul; 22(7):655-662. PubMed ID: 35524907
[TBL] [Abstract][Full Text] [Related]
20. Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis.
Yamaguchi N; Fujii T; Aoi S; Kozuch PS; Hortobagyi GN; Blum RH
Eur J Cancer; 2015 Nov; 51(16):2314-20. PubMed ID: 26343314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
